Shennon Biotechnologies
shennonbio.com
Actively hiring
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$12M
1 round on record
Latest round
$12M
Venture round · Sep 2026 · this month
Team
201-500
employees, estimated range
Backers
3
DCVC, Future Ventures
The money's age
Fresh money
0 months since the last round · not hiring
Momentum
35/100
in the news, fresh money
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Sep 14
Raised a round Venture round $12M · businesswire
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Sep 2026 | $12M | — | businesswire |
Backed byfrom the funds' portfolios and accelerator catalogs
DCVC 
Future Ventures 
NextGen Venture Partners Investors in similar startupsfunds that back the companies most like this one
backs TwoStep, Pumpkin Seed
backs TwoStep
Similar startupsby what they do, their industry and backers
Waypoint Bio is a biotechnology company pioneering the next generation of cell therapies for solid tumors.
Advanced single-cell solutions by Atrandi. Discover high-throughput single-cell technologies for genomics, screening, and biological…
TwoStep Therapeutics. Developing tumor-targeted therapies with broad applicability across solid tumors.
Molecular Cell Architecture - Life at the highest resolution. Pixelgen Technologies' mission is to provide insights into biology at the…
Developing a novel class of cancer therapeutics for solid tumors.
Learn how Dispatch Biotherapeutics is expanding the curative potential of immunotherapies by dispatching its Flare platform to overcome…
News
ShennonBio: Mining rare T cells for solid tumor therapies
ShennonBio is using an ultra-high-throughput microfluidics platform to discover solid tumor targets, identify rare tumor-reactive T cells, and functionally...
Read more
Report
Shennon raises $12m and names new CEO
Shennon Biotechnologies has secured $12 million and appoints new CEO to advance T cell engager programs toward clinical trials for cancer.
Read more
Report
Shennon Biotechnologies Raises $12M in Financing, Appoints Cyril Konto, M.D., as Chief Executive Officer and Unveils Precision Immunotherapy Pipeline
Read more
Report
Shennon Biotechnologies Raises $12 Million, Names Cyril Konto As CEO, And Unveils Precision Immunotherapy Pipeline
Shennon Biotechnologies has raised $12 million in new financing to advance its precision immunotherapy platform and emerging oncology pipeline while appointing biotechnology industry veteran Cyril Konto, M.D., as Chief Executive Officer. This financing wa
Read more
Report
Shennon Biotechnologies Raises $12M in Financing, Appoints Cyril Konto, M.D., as Chief Executive Officer and Unveils Precision Immunotherapy Pipeline
Shennon Biotechnologies Raises $12M in Financing, Appoints Cyril Konto, M.D., as Chief Executive Officer and Unveils Precision Immunotherapy Pipeline
Read more
Report
Financials
Total raised
$12M
Latest round
Venture - Series Unknown
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Venture - Series Unknown | 2026 | $12M | Details |